NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

乾燥症(修格蘭氏症候群):現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Sjogren's Syndrome - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024213
出版日期 內容資訊 英文 185 Pages
商品交期: 3-5個工作天內
價格
乾燥症(修格蘭氏症候群):現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Sjogren's Syndrome - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月09日內容資訊: 英文 185 Pages
簡介

本報告提供乾燥症(修格蘭氏症候群)市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,各市場區隔的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,乾燥症(修格蘭氏症候群)治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 開發平台分析預測

第4章 乾燥症(修格蘭氏症候群)治療概要

第5章 市場動態

第6章 開發平台藥物的專利分析

第7章 開發平台藥物分析

第8章 開發平台藥物概要與開發里程碑

第9章 臨床試驗概要

第10章 開發平台藥物推算核准計劃

第11章 競爭基準為基礎的機會評估

第12章 現在及未來的競爭情形

目錄
Product Code: GERPH1336

GervanoRA's pipeline analysis and opportunity assessment report "Sjogren's Syndrome- Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Sjogren's Syndrome pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Sjogren's Syndrome drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Sjogren's Syndrome area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Sjogren's Syndrome drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of Sjogren's Syndrome historical and forecasted epidemiology based market trends Worldwide. A detailed analytics on the Current Sjogren's Syndrome Market (2020) and the Forecasted Sjogren's Syndrome Market until the year 2030 have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Sjogren's Syndrome Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Sjogren's Syndrome Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Sjogren's Syndrome Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

CHAPTER 02: EXECUTIVE SUMMARY

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

CHAPTER 04: SJOGREN'S SYNDROME THERAPIES OVERVIEW

CHAPTER 05: MARKET DYNAMICS OF SJOGREN'S SYNDROME COMPETITIVE SPACE

CHAPTER 06: PATENT ANALYTICS OF SJOGREN'S SYNDROME PIPELINE DRUGS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF SJOGREN'S SYNDROME

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 09: CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF PIPELINE DRUGS

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

LIST OF TABLES

  • TABLE: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE: PROMINENT LATE CLINICAL STAGE DRUG CANDIDATES TARGETING CAUSE OF SJOGREN'S SYNDROME
  • TABLE: LIST OF PIPELINE MOLECULES WITH TOPICAL AND ORAL ROUTE OF ADMINISTRATION
  • TABLE: PIPELINE DRUGS ALONG WITH ANTICIPATED APPROVAL IN THE US AND EUROPE MARKETS
  • TABLE: PIPELINE DRUGS ALONG WITH ANTICIPATED APPROVAL IN THE ASIAN MARKET
  • TABLE: MARKET RESEARCH DATA ON AVAILABLE SJOGREN'S SYNDROME DRUGS (USD)
  • TABLE: ESTIMATED AVERAGE SELLING PRICES OF LATE-CLINICAL STAGE SJOGREN'S SYNDROME PIPELINE DRUGS
  • TABLE: PERCEIVED VALUE OF SJOGREN'S SYNDROME PRESCRIPTION DRUG BY COMPETITIVE BENCHMARKING
  • TABLE: CURRENTLY AVAILABLE APPROVED DRUGS FOR SJOGREN'S SYNDROME
  • TABLE: MOA AND MOLECULAR TARGET OF THE CURRENTLY PRESCRIBED MEDICATIONS FOR SJOGREN'S SYNDROME
  • TABLE: LIST OF EMERGING BIOLOGIC THERAPIES FOR SJOGREN'S SYNDROME
  • TABLE: LIST OF EMERGING SMALL MOLECULAR THERAPIES FOR SJOGREN'S SYNDROME
  • TABLE: LICENSING DEALS IN SJOGREN'S SYNDROME THERAPEUTIC AREA
  • TABLE: COLLABORATION DEALS IN SJOGREN'S SYNDROME THERAPEUTIC AREA
  • TABLE: FINANCING DEALS IN SJOGREN'S SYNDROME THERAPEUTIC AREA
  • TABLE: MERGER AND ACQUISITION DEALS IN SJOGREN'S SYNDROME THERAPEUTIC AREA
  • TABLE: PATENT FAMILIES OWNED BY SYLENTIS WITH RESPECT TO SJOGREN'S SYNDROME TREATMENT
  • TABLE: PATENT FAMILIES OWNED BY REMEGEN WITH RESPECT TO SJOGREN'S SYNDROME TREATMENT
  • TABLE: PATENT FAMILIES OWNED BY ALPINE IMMUNE SCIENCES WITH RESPECT TO SJOGREN'S SYNDROME TREATMENT
  • TABLE: SJOGREN'S SYNDROME PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE: SJOGREN'S SYNDROME PHASE III PIPELINE MOLECULES
  • TABLE: SJOGREN'S SYNDROME PHASE II PIPELINE MOLECULES
  • TABLE: SJOGREN'S SYNDROME PHASE I PIPELINE MOLECULES
  • TABLE: SJOGREN'S SYNDROME PRE-CLINICAL PIPELINE MOLECULES
  • TABLE: SJOGREN'S SYNDROME EARLY R&D PIPELINE MOLECULES
  • TABLE: TERMINATED AND INACTIVE PIPELINE MOLECULES FOR SJOGREN'S SYNDROME
  • TABLE: PIPELINE DRUGS ALONG WITH ANTICIPATED REGION OF APPROVAL
  • TABLE: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
  • TABLE: MONOCLONAL ANTIBODY DRUGS UNDER DEVELOPMENT
  • TABLE: IMMUNOMODULATORY DRUGS UNDER DEVELOPMENT
  • TABLE: GENE-BASED THERAPIES UNDER DEVELOPMENT
  • TABLE: PROTEIN KINASE INHIBITORS UNDER DEVELOPMENT
  • TABLE: OTHER DRUG CLASS' DRUG CANDIDATES
  • TABLE: LIST OF SJOGREN'S SYNDROME PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE: LIST OF COMPANIES DEVELOPING BIOLOGIC MOLECULES
  • TABLE: SJOGREN'S SYNDROME PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE: REGION WISE STATISTICS, COMPANY COUNT OF SJOGREN'S SYNDROME AND PIPELINE DRUGS COUNT
  • TABLE: SYLENTIS' TIVANISIRAN PHASE III TRIAL DESIGN
  • TABLE: RESOLVE THERAPEUTICS' RSLV-132 PHASE II TRIAL DESIGN
  • TABLE: TEARSOLUTIONS INC'S LACRIPEP PHASE II TRIAL DESIGN
  • TABLE: OSE IMMUNOTHERAPEUTICS/ SERVIER'S OSE-127/S95011 PHASE I TRIAL DESIGN
  • TABLE: KINIKSA PHARMACEUTICALS LTD'S KPL-404 PHASE I TRIAL DESIGN
  • TABLE: PHASE II ONGOING CLINICAL TRIALS
  • TABLE: PHASE III RECENTLY COMPLETED CLINICAL TRIALS
  • TABLE: PHASE II RECENTLY COMPLETED CLINICAL TRIALS
  • TABLE: PHASE I RECENTLY COMPLETED CLINICAL TRIALS
  • TABLE: PLANNED CLINICAL TRIALS
  • TABLE: GERVANORA ESTIMATED APPROVAL TIMELINES VS ACTUAL APPROVAL DATE
  • TABLE: ESTIMATED APPROVAL TIMELINES OF LATE CLINICAL STAGE (PHASE II AND PHASE III) DRUG CANDIDATES
  • TABLE: LIST OF EMERGING COMPANIES WITH REGULATORY ALLOWANCES
  • TABLE: PIPELINE ASSETS OF SYLENTIS

LIST OF FIGURES

  • FIGURE: KEY EVENTS IN THE SJOGREN'S SYNDROME COMPETITIVE SPACE
  • FIGURE: FORECASTED ANNUAL INCREASE IN SJOGREN'S SYNDROME DRUG MARKET
  • FIGURE: SJOGREN'S SYNDROME TOTAL DRUG MARKET SHARE
  • FIGURE: EXPECTED PEAK SALES OF TIVANISIRAN
  • FIGURE: COMPARISON OF EXPECTED PEAK SALES OF LACRIPEP, IANALUMAB, VIB4920 AND RSLV-132
  • FIGURE: COMPARISON OF ESTIMATED SALES FOR THE KEY LATE CLINICAL STAGE DRUGS (IN $MILLIONS)
  • FIGURE: ESTIMATED MARKET SHARE OF NEW ENTRANTS IN 2028
  • FIGURE: SJOGREN'S SYNDROME DRUG PIPELINE SCENARIO
  • FIGURE: WORLDWIDE (WW) PREVALENCE OF SJOGREN'S SYNDROME WITH LOWEST AND HIGHEST % OF WW POPULATION
  • FIGURE: US PREVALENCE OF SJOGREN'S SYNDROME WITH LOWEST AND HIGHEST % OF US POPULATION
  • FIGURE: EUROPE PREVALENCE OF SJOGREN'S SYNDROME WITH LOWEST AND HIGHEST % OF EUROPE POPULATION
  • FIGURE: SJOGREN'S SYNDROME DEAL ANALYTICS BY DEAL TYPE
  • FIGURE: SJOGREN'S SYNDROME DEAL ANALYTICS BY GROUPED ANNUAL DEAL FREQUENCIES
  • FIGURE: DISEASE AREA DEAL BREAKDOWN FOR THE YEAR OF 2019-2020 WITH RESPECT TO ALPINE IMMUNE SCIENCES
  • FIGURE: BREAKDOWN OF DEALS INVOLVING ALPINE IMMUNE SCIENCES WITH RESPECT TO SJOGREN'S SYNDROME
  • FIGURE: DEALS ANALYTICS BY ACTIVE PLAYERS IN SJOGREN'S SYNDROME THERAPEUTIC MARKET
  • FIGURE: BREAKDOWN OF INTELLECTUAL PROPERTY FILED ACROSS THE GLOBE FOR SJOGREN'S SYNDROME TREATMENT
  • FIGURE: GEOGRAPHICAL DISTRIBUTION OF PATENT FAMILIES OWNED BY TEARSOLUTIONS
  • FIGURE: GEOGRAPHICAL BREAKDOWN OF PATENTS AND PATENT APPLICATIONS OWNED BY KINIKSA PHARMACEUTICALS
  • FIGURE: GEOGRAPHICAL DISTRIBUTION OF PATENT FAMILIES OWNED BY XTLBIO
  • FIGURE: GEOGRAPHICAL BREAKDOWN OF PATENT FAMILIES OWNED BY CYTODYN
  • FIGURE: PIPELINE MOLECULES - CLINICAL VS NON-CLINICAL MOLECULES
  • FIGURE: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE: SCHEMATIC REPRESENTATION OF WORLDWIDE ANTICIPATED DRUG APPROVALS
  • FIGURE: GRAPHICAL REPRESENTATION OF PIPELINE DRUGS FOR APPROVAL REGIONS & HSD
  • FIGURE: SJOGREN'S SYNDROME PIPELINE ANALYTICS BY ROA
  • FIGURE: SJOGREN'S SYNDROME PIPELINE ANALYTICS BY INJECTABLE ROA
  • FIGURE: INJECTABLE PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE: SJOGREN'S SYNDROME PIPELINE DRUGS ANALYTICS, BIOLOGICALS VS SMALL MOLECULES
  • FIGURE: MOLECULE TYPE PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE: SJOGREN'S SYNDROME PIPELINE DRUG ANALYTICS BY COMPANY TYPE
  • FIGURE: GEOGRAPHICAL CATEGORIZATION OF COMPANIES
  • FIGURE: PRO-F SCALE, ESSPRI SCORE, FACIT MEASURED PARAMETER AT DAY 99 IN PHASE II TRIAL OF RSLV-132
  • FIGURE: MAJOR PHASE II ONGOING CLINICAL TRIALS WITH RESPECT TO NUMBER OF PARTICIPANTS ENROLLED
  • FIGURE: MAJOR PHASE II RECENTLY COMPLETED CLINICAL TRIALS
  • FIGURE: TOP THREE COMPANIES WITH RESPECT TO R&D EXPENSES INCURRED FOR SJOGREN'S SYNDROME TREATMENTS
  • FIGURE: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE: EXPECTED MARKET ENTRY OF PRODUCT CANDIDATES DEVELOPED WITH RESPECT TO SJOGREN'S SYNDROME
  • FIGURE: TIME LINE OF PATENT AND PATENT APPLICATION EXPIRIES WITH RESPECT TO SJOGREN'S SYNDROME TREATMENT
  • FIGURE: RANK OF EMERGING COMPANIES CONSIDERING PARTNERING ACTIVITIES PERTAINING TO SJOGREN'S SYNDROME
  • FIGURE: SOME OF SYLENTIS' KEY COLLABORATIVE PROJECT PARTNERS